Paul van den Brekel
Commercial & Financial Officer
Received a M.Sc. in Business Administration at the University of Groningen (1993). Acquired “hands on” global pharmaceutical industry experience in the 3 key markets (US, Japan and Europe) in increasingly senior operations, sales, marketing, finance and general management positions. Both at national as well as regional level, initially at Organon (1993 – 2007) followed by Schering-Plough (2007-2008) and in most recent years with AstraZeneca (2009-2017). Joined CyTuVax as Commercial & Financial Officer in September 2017 in order to secure future funding and to prepare next steps beyond the on-going phase II study for Hepatitis B vaccination in non-responders. At the same time expanding the opportunities with the proprietary platform technology both in the prophylactic as well as the therapeutic application.